Loading…
← CockpitCompetitor Analysis › 688029.SS Micro-Tech (Nanjing) Co., Ltd. Class AOpen in the cockpit ↗

Micro-Tech (Nanjing) Co., Ltd. Class A688029.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese maker of endoscopy accessories — biopsy forceps, stents and snares — used with gastrointestinal endoscopes.

≈ A Chinese endoscopy-accessories supplier akin to a Boston Scientific Endoscopy nicheMomentum leader 93
Mkt cap
$2.33B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$34.7M
20-day average traded
Fwd P/E
28.1×
forward earnings
ROIC−WACC
+8.5 pp
WACC 7.9%
Hurdle
-7 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥81.90
1D-3.0%
1W-2.3%
1M-0.6%
3M+12.2%
6M-0.5%
YTD+0.4%
1Y+0.3%
ATR %4.5%
52w lowhigh8.9% off high

What Micro-Tech (Nanjing) does

Chinese maker of endoscopy accessories — biopsy forceps, stents and snares — used with gastrointestinal endoscopes.

Its accessories are single-use, so revenue repeats with every procedure instead of resting on one-off equipment sales. A large part of sales goes overseas, mostly through local distributors and large device makers that resell the products.

In one line: A Chinese endoscopy-accessories supplier akin to a Boston Scientific Endoscopy niche.

Products and services

  • Biopsy forceps
  • Endoscopic stents
  • Polypectomy snares
  • Hemostasis clips

Customers

  • Gastroenterologists/hospitals
  • Endoscope OEMs (distribution partners)

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Endoscopy accessories/consumables

What could go right

  • Global endoscopy procedure-volume growth
  • International distribution expansion

What could go wrong

  • Volume-based procurement price cuts (China)

Moat: narrow (regulatory licence, distribution). Broad global distribution network and device approvals across many markets.

Headquarters: Nanjing, Jiangsu, China · Founded: 1999 · Employees: 2,433

Named competitors

Micro-Tech (Nanjing) at a glance

Size Micro-Tech (Nanjing) (688029.SS) is a China Health Care company (Medical Specialties) with a market value of $2.33B, the 1027th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥81.90 on 18 Nov 2026.

Performance Over six months the shares fell 0.5%, against +1.1% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 6.3% over the last twelve months (peer median +7.5%); the operating margin is 18.5% (peer median 10.7%).

Valuation It trades at 28.1× forward earnings against a peer median of 24.2× (8th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 8.5 points above its cost of capital (7.9% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 104688029.SS 101
Six months, rebased to 100: Micro-Tech (Nanjing) against the median of its 20 peers (local-currency closes).

Micro-Tech (Nanjing) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.32BCN¥3.17BCN¥2.74BCN¥2.39BCN¥1.97B
Revenue growth—+16%+14%+22%—
Gross profitCN¥2.14BCN¥1.92BCN¥1.77BCN¥1.48BCN¥1.14B
EBITDAn/aCN¥741MCN¥702MCN¥531MCN¥338M
Net incomeCN¥477MCN¥570MCN¥553MCN¥486MCN¥331M
Free cash flowCN¥535MCN¥468MCN¥400MCN¥360MCN¥84.7M
Capital expenditureCN¥178MCN¥255MCN¥270MCN¥256MCN¥213M
Total debtCN¥322MCN¥251MCN¥89.0MCN¥45.1MCN¥11.9M

Quarterly statements and history in the cockpit →

Micro-Tech (Nanjing) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-25%0%+25%EKTA-B3005292276NEOG002901MOVEMETNEBODRW86951ESTAVCYTBONEXOBCKCELCATRCMEDSKAN688029.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Micro-Tech (Nanjing) is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×100×200×EKTA-B3005292276NEOG002901MOVEMETNEBODRW86951VCYTBONEXATRCMEDSKAN688029.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Micro-Tech (Nanjing) is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%EKTA-B3005292276002901EBODRW86951VCYTBONEXOBCKATRCSKAN688029.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Micro-Tech (Nanjing) is the large dot.

Micro-Tech (Nanjing) competitors and peer comparison

Head to head with its named competitors (688029.SS vs BSX vs 7733.T vs CNMD)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Micro-Tech (Nanjing) 688029.SS$2.33B0%+6%18%28.1×11.9%
Boston Scientific BSX$63.3B-23%+9%21%14.1×5.8%
Olympus 7733.T$12.7B+5%+9%18%18.7×-6.5%
CONMED CNMD$1.43B+30%+2%2%10.4×31.6%

How Micro-Tech (Nanjing) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Micro-Tech (Nanjing) against its 20 peers (data as of 18 Nov 2026)
Measure688029.SSPeer medianRank in peer set
1-month return-0.6%-1.6%10th highest of 21
6-month return-0.5%+1.1%9th lowest of 20
Distance from 52-week high-8.9%-24.0%7th highest of 21
Revenue growth (TTM)+6.3%+7.5%10th lowest of 20
Operating margin18.5%10.7%5th highest of 20
Forward P/E28.1×24.2×8th most expensive of 18
Growth the price implies (Req g, 7 yrs)11.9%9.2%6th most demanding of 13
Growth delivered (Del g)+19.2%+10.3%4th highest of 13
Hurdle (Req g minus delivered)-7.3 pp-2.5 pp6th least demanding of 13
ROIC minus cost of capital+8.5 pp-0.6 pp6th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Micro-Tech (Nanjing) 688029.SSChina$2.33B0%+6%18%28.1×11.9%+19.2%
Elekta EKTA-B.STSweden$2.35B0%-7%6%15.3×10.7%+4.0%
Jafron Biomedical 300529.SZChina$2.35B+3%+1%37%24.3×6.1%+0.6%
Shanghai Conant Optical 2276.HKHong Kong$2.25B-17%+8%29%22.1×-1.1%+14.1%
Neogen NEOGUnited States$2.42B+25%0%0%32.6×n/an/a
Double Medical Technology 002901.SZChina$2.43B-2%+13%26%24.2×7.6%+10.4%
Medacta MOVE.SWSwitzerland$2.48B-28%+8%15%24.0×n/an/a
Metall Zug METN.SWSwitzerland$2.19B+20%0%-10%139.8×n/an/a
EBOS EBO.AXAustralia$2.50B+7%+3%3%15.7×4.7%+6.8%
Draegerwerk AG & Co. KGaA DRW8.DEGermany$2.13B+25%+5%7%10.2×-10.2%+0.4%
JEOL 6951.TJapan$2.12B-2%-15%12%15.5×22.2%+10.2%
Establishment Labs ESTAUnited States$2.11B+1%+38%-7%n/an/an/a
Veracyte VCYTUnited States$2.06B-43%+18%16%17.1×18.0%+34.5%
Bonesupport BONEX.STSweden$2.06B+21%+25%25%61.5×12.6%+45.4%
Ottobock SE & Co. KGaA OBCK.DEGermany$2.65B-30%+5%17%12.3×-1.2%+8.0%
Celcuity CELCUnited States$2.73B-60%n/an/an/an/an/a
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
SKAN SKAN.SWSwitzerland$1.85B+40%+9%11%49.5×13.8%+11.7%
Molbio Diagnostics MOLBIO.NSIndia$1.85Bn/a+35%17%n/an/an/a

Questions

Who are Micro-Tech (Nanjing)'s main competitors?
Named competitors: Boston Scientific (BSX), Olympus (7733.T), Cook Medical (private) (private or unlisted), ConMed (CNMD). The cockpit's measured peer set (industry) also includes Elekta (EKTA-B.ST), Jafron Biomedical (300529.SZ), Shanghai Conant Optical (2276.HK), Neogen (NEOG), Double Medical Technology (002901.SZ), Medacta (MOVE.SW).
Is Micro-Tech (Nanjing) expensive compared with its peers?
On forward p/e it trades at 28.1× against a peer median of 24.2×, 8th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has Micro-Tech (Nanjing) stock performed?
Over six months to 18 Nov 2026 the shares returned -0.5% against +1.1% for the median peer; over one year +0.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.